The Centers for Disease Control and Prevention suggests the challenge test for children whose blood lead levels are 1.21-2.12 pmol/L (2544 pg/dL 
The Centers for Disease Control and Prevention (CDC) recommends that the calcium disodium edetate (CaNa2EDTA) challenge test be considered for children who have blood lead levels of 1.21-2.12 pmol/L (25-44 pg/dL) to determine whether chelation is indicated (1) . This recommendation is based on a past study (2, 3) . However, the challenge test is a potentially difficult procedure because of the required 8-hr urine collection, often on an active toddler. By identifying children who are likely to have a negative challenge test, a medical provider can minimize the number of children undergoing this test. The objective of this study was to identify factors likely to predict the outcome of challenge tests.
Materials and Methods
The Finger Lakes Lead Poisoning Prevention and Treatment Center at Rochester General Hospital (Rochester, NY) offers medical services to children who have elevated blood lead levels in a nine-county area surrounding Rochester, New York. Children can be referred to this center by their physicians for a challenge test with CaNa2EDTA if their blood lead levels are 1.21-2.12 pmol/L (25-44 pg/dL). Parents of all children admitted to Rochester General Hospital sign a consent form on admission; the form allows staff physicians to review the chart and abstract data for research purposes. We obtained a venous lead level, erythrocyte protoporphyrin (EP) level, serum iron, total iron binding capacity (TIBC), and hematocrit immediately before administering CaNa2EDTA. We administered CaNa2EDTA at a dose of 500 mg/mi2 either intravenously over 1 hr or intramuscularly mixed 3:1 by volume with 2% lidocaine; the result of a challenge test is unaffected by whether the CaNa2EDTA is administered intramuscularly or intravenously (4) . Subsequently, an 8-hr urine sample was collected and stored in an acid-washed, leadfree plastic container. Maintenance oral fluid intake was encouraged throughout the urine collection; if oral intake fell below maintenance in any 2-hr period during the 8-hr collection, we administered intravenous fluids at a maintenance rate.
Blood and urine lead levels were measured by graphite furnace atomic absorption spectrometry (5) . Blood samples were assayed twice, and the mean was reported. The laboratory participates in a proficiency testing program for the blood lead assay. There is no proficiency testing program for the determination of lead in urine; however, quality control is conducted on urine samples acquired from the New York State Department of Health (Albany, NY).
During 1997 and 1998, 62 quality control samples were assayed, and the values of all were within two standard deviations of the mean (6) . The EP level was assayed fluorimetrically (74. Serum iron was measured using Ferrozine (Hach Chemical Co., Ames, IA) to form a colored complex with reduced iron (8) . TIBC was measured using Ferrozine (9) .
The results of a challenge test were eligible for analysis if there were no losses of urine during the 8-hr urine collection. We compared the mean age and blood lead level at the time of referral among the excluded challenge tests and the eligible challenge tests to assess whether the two groups were comparable. pg/dL) and . 0.62 jig/dL (2 35 pg/dL) strata. RATE was dichotomized into < 0 ggldL/day and 2 0 pg/dL/day strata. We introduced all combinations of the respective variables for each of the two models into forced-entry logistic regression using SPSS software (SPSS, Inc., version 4.0, Chicago, IL). Our objective was to find the model and set of independent variables that would correctly classify all true-positive challenge tests (i.e., 100% sensitivity) while minimizing the number of true-negative challenge tests that were falsely classified.
Results
A total of 217 children were referred between January 1992 and September 1998 for 253 challenge tests (mean 1.2 challenge tests per child; range 1-5). Among these children, 51% were male; 68% were African American, 14% were Hispanic, 16% were white, and 2% were an undefined race. The mean age at the time of the challenge test was 37.7 months, and the mean blood lead level at the time of referral was 1.83 pmol/L (38 pg/dL); all blood lead levels were assayed on venous blood. Table 2 .
Among the eligible 178 challenge tests, 40 (22%) were positive and 138 were negative. Table 3 lists the proportion of challenge tests that were positive at different strata of blood lead levels among the eligible challenge tests. There were no positive challenge tests among children with a blood lead level < 1.40 pmol/L (< 29 pg/dL), whereas 71% of the challenge tests were positive among children with a blood lead level 2.41-2.61 jmol/L (50-54 pg/dL). Restricting the sample to children with EP levels . 0.62 jmol/L (. 35 pg/dL) resulted in higher proportions of positive challenge tests for nearly every stratum of blood lead level ( Table 2) . (Table 4) . Of the two models for which multivariate logistic regression was performed, the second model (a medical provider who obtains a repeat blood lead level 2-4 weeks after diagnosing a child with a moderately elevated blood lead level) was the preferential scenario for predicting the outcome of a challenge test when blood lead level at the time of chelation, age, and RATE were entered into the analysis. Table 5 lists the predicted probability of a challenge test according to this logistic regression model by blood lead level, age, and RATE. A predicted probability of 0.15 was the threshold above which all true-positive challenge tests were identified (100% sensitivity), but 39% of true-negative challenge tests were falsely classified as positive.
Discussion
The CDC recommends that the CaNa2-EDTA challenge test be considered for children who have blood lead levels of 1.21-2.12 pmol/L (25-44 pg/dL) to determine whether chelation is indicated (1). However, some authors no longer recommend the challenge test because of the potential toxicity of CaNa2EDTA (11, 12) , and the difficulty of obtaining complete urine samples (12, 13) .
The assertion that CaNa2EDTA is toxic arises from a study reporting that rats receiving a single dose of CaNa2EDTA had an increase in brain lead level (14) . In that study, the dose of CaNa2EDTA associated with increased brain lead levels was 150 mg/kg, but this phenomenon did not occur at a dose of 75 mg/kg. Because an even lower dose of CaNa2EDTA, approximately 25 mg/kg, is recommended for the CaNa2-EDTA challenge test (1), the results of that study are not generalizable to children who are candidates for the challenge test.
The assertion that it is difficult to obtain complete urine samples is accurate. However, this argues not for the abandonment of this test, but rather that it be conducted by personnel experienced in collecting urine from young children. In 1997, our center obtained complete collections on 83% of children; the remaining children sustained inconsequential urine losses during the last 1-2 hr of the collection, a period when CaNa2EDTA-induced lead excretion is minimal.
At present, the blood lead level has become the sole factor determining whether a child undergoes chelation (1). Nevertheless, children with comparable blood lead levels can have great differences in body lead burden and thus different degrees of lead diuresis in response to a chelating agent. For example, only 3% of children with an EP level < 0.62 imol/L (< 35 pg/dL) had a positive challenge test, in comparison to 31% of children who had an EP level > 0.62 pmol/L (. 35 pg/dL) despite comparable blood lead levels. This reflects the heterogeneity that exists within the population of lead-exposed children and highlights the limitations of the blood lead level in determining whom to chelate. Authors have raised this issue and argued that the challenge test is useful for identifying whom to treat when blood lead levels are moderately elevated (15, 16) . Our study supports this contention. Among children who have comparable blood lead levels, the challenge test differentiates children who will not have a significant CaNa2EDTA-induced lead diuresis, and thus will not benefit from chelation, from those who will have a significant CaNa2EDTA-induced lead diuresis, and thus are more likely to benefit from chelation. Nevertheless, further research is needed to define what constitutes a significant level of chelationinduced lead diuresis (13) , preferably by linking it to neurocognitive outcomes.
Our study found that readily obtainable tests can identify children likely to have a negative challenge test. A low EP level is excellent at identifying such children; only 3% of challenge tests with an EP level < 0.62 pmol/L (< 35 pg/dL) were positive. This finding is comparable to the 4.8% reported by Markowitz et al. (15) . A decreasing blood lead level is a fair predictor of a negative challenge test; 86% of children whose blood lead level was decreasing (i.e., RATE < 0 pg/dL/day) had a negative challenge test. Additionally, certain blood lead levels were also predictive of a negative challenge test; no challenge tests were positive at blood lead levels < 1.40 pmol/L (< 29 pg/dL). Previous studies report that iron deficiency is associated with a lowered likelihood of a positive challenge test (10, 15) . Our study found that iron saturation did not reliably distinguish the outcome of a challenge test; this is not surprising because iron status was previously noted to be weakly associated with the outcome of the challenge test (10) 4 weeks of the diagnosis. Additionally, because proficiency testing programs for the assay of lead in urine do not currently exist, providers should conduct the challenge test as we described in "Methods" and be assured that their population has comparable rates of positive challenge tests by strata of blood lead level.
Other studies have reported rates of positive challenge tests comparable to those in our study (15, 17, 18 
